Preliminary observations of single-agent docetaxel as neoadjudant therapy for locally advanced prostrate cancer

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 15, 2001, Pages 45-48

  Dreicer, Robert ^b   Klein, Eric A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; EDEMA; FATIGUE; HUMAN; MALE; MALE GENITAL TRACT CANCER; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RASH; TREATMENT OUTCOME;

EID: 0034784577     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26900     Document Type: Article

References (16)

1. Proceedings: The natural history of prostatic cancer
2. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
3. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control
4. Neoadjuvant hormone therapy before radical prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center trials
5. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial
6. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results
7. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer
8. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer
9. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
10. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy: A comparative study of radical prostatectomies
11. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy
12. Contemporary results of anatomic radical prostatectomy
13. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer
14. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer
15. Metastatic prostate cancer: Assessment of response to systemic therapy